Jakub Hort, MD, PhD

Neurology — International Clinical Research Center of St. Anne's University Hospital Brno, Czechia

LeadR Profile

1 308 ScienceLeadR Reputation 1308
Network Map

Neurology

Subspecialties: Psychiatry - Psychology - Genetics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Short Biography

Dr. Hort is a Professor of neurology at Department of Neurology, Charles University, 2nd Medical Faculty and Motol University Hospital, Prague, Czech Republic and PI of the Czech Brain Ageing Study (CBAS), which is conducted in cooperation with the International Clinical Research Center in Brno, Czech Republic. CBAS is an unique longitudinal prospective study established in 2011 to explore the early functional, metabolic and structural biomarkers of Alzheimer ́s Disease (AD) and other dementias. (Refer to: www.cbas.cz) Dr. Hort was elected chairman of Section on cognitive neurology of the Czech Neurological Society (2005-2018, 2023-2027). Dr. Hort served also as a co-chair of the European Academy of Neurology (EAN) Scientist Panel Dementia and Cognitive Neurology (2015-2019). Dr. Hort authorized European guidelines on AD and participated in EAN guidelines on non-Alzheimer dementias and combination therapy for AD. Dr. Hort has been honored to become Courtesy Professor at University of South Florida, School of Aging Studies in 2019. He is a member of Expert Advisory Panel of Alzheimer Europe and member of Scientific leadership Group of International Registry on Alzheimer Disease (InRAD). Dr. Hort is an expert in translational research and has introduced a novel method of a human variant of the Morris Water Maze (hMWM) into AD research. Dr. Hort has published several papers indicating that spatial navigation is impaired early in the course of the disease and represents distinguished cognitive domain. Recently dr. Hort has been involved in numerous initiatives to bring novel technologies of quantum computing, artificial intelligence (AI), machine learning, virtual reality and blockchain to both AD research and clinical practice. Dr. Hort is co-founder of telemedicine/blockchain projet Alzheimerchain and NFT Non-fungible brain project. He has launched very successfull mobile app Terrapino for prevention of AD and promotion of healthy aging - www.terrapino.com He is a medical advisor of AI company Neurona lab developing MRI, PET and voice AI solutions in aging and cognitive disorders. Dr. Hort has participated in numerous drug development projects as a consultant, SAB member and principal investigator as well. He published more than 300 scientific articles receiving more than 10k citations and H-index of 46 (2025). He has served as a reviewer for several peer reviewed journals and international grant agencies. In 2011 he founded Czech Alzheimer fund, which sponsored many research projects and scholarships for young scientists.

Organizations

Career arc: 1999 - 2026

Source: PubMed

Charles University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 369

Citations

Citations: 11 740 1st author: 16 Last author: 133 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Amyloid, p-tau, neurofilament light, and α-synuclein cerebrospinal fluid biomarkers across Alzheimer's disease, dementia with Lewy bodies, and Parkinson's disease.
dementia, lewy bodies, parkinson disease, alzheimer disease, pathology, biomarkers, risk factors, amyloid, synucleins, neurodegenerative diseases, cognition
Alzheimers Dement (Amst)20260
APOE-stratified genome-wide association analyses provide insights into the genetic etiology of Alzheimers's disease.
genes, dementia, genome, therapeutics, apolipoproteins e
Nat Genet20260
Expert opinion on Alzheimer's disease diagnostics and management in Central Eastern European countries representing 88 million population.
alzheimer disease, neurosciences, therapeutics
Neurol Sci20260
Demographic and clinical influences on emotion prosody recognition.
life style, emotions, stress, physiological, social cognition, mobile applications, research, demography, individuality
Front Psychol20260
Correction: The impact of spatial normalization strategies on the temporal features of the resting-state functional MRI: spatial normalization before rs-fMRI features calculation may reduce the reliability.Front Neurosci20260

Clinical Studies 7

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 2 4
Phase 3 2
N/A 1

By status:

Completed 3
Recruiting 2
Active not recruiting 1
Not yet recruiting 1

By type:

Interventional 6
Observational 1

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 2
multicentricup10 5

Main Topics

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Phase 2a Multi Center Randomized Parallel Group Double Blind and Placebo controlled Clinical Trial to Assess Safety and Tolerability as well as Explorative Efficacy of the Orthosteric Selective Muscarinic M1 Agonist NSC001 in Mild to Moderate Alzheimer s Disease
2024-518563-35-00 — safety, alzheimer disease, multiple chronic conditions, therapeutics
Phase 2Recruiting2025
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT KarX EC for the Treatment of Agitation Associated with Alzheimer s Disease
2025-520612-34-00 — safety, alzheimer disease, therapeutics
Phase 3Not yet recruiting2025
InRAD Observational Study
NCT07213700 — registries, dementia, safety, alzheimer disease, cognitive dysfunction, methylenebis(chloroaniline), cognition disorders, foundations, research, therapeutics
N/ARecruiting2026

LeadR Networks

Main global connection map